This Is a Fast-Moving Area of Research, so for Now We Need to Proceed With Caution and Reassess

“This is a fast-moving area of research, so for now we need to proceed with caution and reassess as more data becomes available,” said Yvette LaCoursiere, a professor of obstetrics, gynecology and reproductive sciences at the University of California at San Diego and an author of the new guidance from the American College of Obstetricians and Gynecologists.

ACOG released that guidance in late October, recommending that patients discontinue GLP-1 use one to two months before a planned pregnancy.

The recommendation lands as the collision between a blockbuster drug class and reproductive biology comes into sharper focus. Nearly 25 million U.S. women aged 18 to 44 — almost half of all women of reproductive age — are eligible for GLP-1 medications.

More than 40 percent of pregnancies in this country are unplanned. Combined, those statistics pull the prescribing conversation out of fertility clinics and into primary care offices, where the first discussion about a GLP-1 often happens.

ACOG estimates that around one in 300 women are exposed to GLP-1 medications during pregnancy. Existing research doesn’t suggest a high risk of congenital issues from use before or during pregnancy, the college said, but there is little safety data to draw definitive conclusions.

The guidance also recommends against taking GLP-1 medications while breastfeeding preterm infants and urges careful monitoring of neonatal weight gain if mothers use the drugs while breastfeeding full-term infants.

This Is a Fast-Moving Area of Research, so for Now We Need to Proceed With Caution and Reassess
Photo: NPR

A study published in August in Heart, Lung and Circulation adds a new physiological data point. Researchers at Adelaide University, led by S. Cho and M. Lock, administered semaglutide to seven pregnant sheep and used MRI to track maternal hemodynamics and fetal oxygenation. Within two hours, maternal cardiac output dropped significantly, reducing uterine blood flow and lowering fetal arterial oxygen pressure.

“Oxygen is essential for healthy fetal growth and development, so any reduction in its supply raises questions about what might happen if exposure to the drug continues throughout pregnancy,” senior researcher Janna Morrison told Medical Xpress. The authors emphasized the findings show acute effects in an animal model, not long-term outcomes in humans.

“While weight-loss medications have become incredibly popular, there’s still a lot we don’t know about how they might affect a developing baby,” Lock said. “In this study we wanted to understand what happens to the mother’s cardiovascular system and the blood and oxygen supply to the fetus when semaglutide is administered during pregnancy.”

“Within two hours of administering semaglutide, we found that the amount of blood pumped by the mother’s heart had significantly decreased, reducing blood flow to the uterus and lowering oxygen levels in the developing fetus.”

“Oxygen is essential for healthy fetal growth and development, so any reduction in its supply raises questions about what might happen if exposure to the drug continues throughout pregnancy.”

“Our findings suggest a potential risk to fetal development, but we haven’t yet established whether these short-term changes affect fetal growth, what happens over a longer period of semaglutide use or whether similar effects could occur in human pregnancies,” Morrison said.

Human observational data remains thin but not entirely absent. A 2024 prospective study published in BMJ Open included 168 pregnancies with early accidental exposure to GLP-1 medicines and did not identify an increased risk of major birth defects compared with reference groups. That study and others like it examine exposure windows that typically end once pregnancy is confirmed — not continued use through gestation.

Adelaide research finds Ozempic and Wegovy pose risks to unborn babies — 7NEWS

The fertility twist complicates the picture further. GLP-1s can restore ovulation in patients with metabolic dysfunction, fueling a social-media phenomenon dubbed “Ozempic babies,” NPR reported. Dr. Amy Valent of Oregon Health and Science University told NPR’s Short Wave that the drugs may boost fertility for some, leading to more planned and unplanned pregnancies.

But the medications carry gastrointestinal side effects — vomiting chief among them — that can compromise the reliability of oral contraceptives. Tirzepatide in particular has been found to reduce the pill’s bioavailability. Patients experiencing significant GI side effects or taking tirzepatide should either switch to a non-oral contraceptive or add a barrier method after starting a GLP-1 and after each dose increase.

For patients using GLP-1s to manage existing diabetes, stopping the drug introduces a different urgency. Glucose levels can rise quickly. “You want to make sure they have a really tight follow-up with maternal-fetal medicine or endocrinology,” said Stacey Ehrenberg, MD, speaking to Medscape. The semaglutide label puts the discontinuation window at two months before a planned pregnancy, based on the drug’s long half-life.

Gty pregnant woman with iv
Photo: Medscape

“If they are trying to conceive, then involve the obstetric team and the maternal-fetal medicine team and the dietitian team early, so that when they become pregnant, there’s a seamless transition,” Ehrenberg said.

ACOG’s guidance stops short of declaring the drugs unsafe; it declares the evidence insufficient. The consensus calls for balancing the benefits of breastfeeding against theoretical risks of infant exposure, with close attention to maternal nutrition, hydration, micronutrient status, and infant growth milestones if a GLP-1 is used during lactation. Australia’s Therapeutic Goods Administration reiterates the recommendation against use during pregnancy and advises effective contraception during treatment.

The sheep study was published as a conference abstract; its DOI is 10.1016/j.hlc.2026.07.885. ACOG’s clinical guidance arrived in late October. The next round of human data will determine whether the caution holds or shifts.